TherapeuticsMD, Inc. (TXMD)
Largest Insider Buys in Sector
TXMD Stock Price History Chart
TXMD Stock Performance
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and …
Insider Activity of TherapeuticsMD, Inc.
Over the last 12 months, insiders at TherapeuticsMD, Inc. have bought $9,138 and sold $43,684 worth of TherapeuticsMD, Inc. stock.
On average, over the past 5 years, insiders at TherapeuticsMD, Inc. have bought $5.66M and sold $7.95M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Collins Cooper C. (director) — $9,138.
The last purchase of 4,094 shares for transaction amount of $7,099 was made by Collins Cooper C. (director) on 2024‑08‑22.
List of Insider Buy and Sell Transactions, TherapeuticsMD, Inc.
| 2024-08-22 | director | 4,094 0.0352% | $1.73 | $7,099 | -6.29% | |||
| 2024-08-21 | director | 1,200 0.0105% | $1.70 | $2,039 | -2.96% | |||
| 2023-12-07 | Sale | Chief Executive Officer | 4,550 0.0421% | $2.24 | $10,187 | -9.03% | ||
| 2023-12-06 | Sale | Chief Executive Officer | 14,500 0.1412% | $2.31 | $33,496 | -7.97% | ||
| 2023-04-26 | Sale | Chief Executive Officer | 692 0.0079% | $3.64 | $2,518 | -25.21% | ||
| 2023-04-12 | Sale | Chief Executive Officer | 1,170 0.013% | $3.65 | $4,276 | -23.69% | ||
| 2023-01-27 | Sale | Prin. Fin. and Acctg. Officer | 49 0.0005% | $5.09 | $249 | -30.90% | ||
| 2023-01-26 | Sale | Prin. Fin. and Acctg. Officer | 1,648 0.0183% | $5.08 | $8,371 | -27.36% | ||
| 2023-01-24 | Sale | Prin. Fin. and Acctg. Officer | 7 <0.0001% | $5.31 | $37 | -29.48% | ||
| 2023-01-23 | Sale | Prin. Fin. and Acctg. Officer | 1,302 0.0145% | $5.34 | $6,950 | -30.45% | ||
| 2022-12-30 | Sale | director | 29,000 – | $1,333.00 | $38.66M | -31.84% | ||
| 2022-12-09 | Sale | Co-Chief Executive Officer | 320 0.0035% | $6.31 | $2,020 | -39.72% | ||
| 2022-12-09 | director | 14,825 0.1558% | $6.09 | $90,284 | -39.72% | |||
| 2022-12-08 | director | 300 0.0032% | $5.83 | $1,749 | -35.20% | |||
| 2022-12-07 | Sale | director | 3,922 0.038% | $5.26 | $20,635 | -35.44% | ||
| 2022-12-07 | director | 20,113 0.2099% | $5.66 | $113,890 | -35.44% | |||
| 2022-12-06 | Sale | General Counsel | 1,048 0.0106% | $4.95 | $5,185 | -28.06% | ||
| 2022-12-06 | Sale | Interim CFO/CAO/VP of Finance | 910 0.0089% | $4.78 | $4,345 | -28.06% | ||
| 2022-12-06 | Sale | Co-Chief Executive Officer | 935 0.0094% | $4.92 | $4,602 | -28.06% | ||
| 2022-12-06 | Sale | Co-Chief Executive Officer | 440 0.0044% | $4.92 | $2,165 | -28.06% |
Insider Historical Profitability
| Collins Cooper C. | director | 52016 0.451% | $1.37 | 9 | 1 | <0.0001% |
| Finizio Robert G | CEO | 17991637 156.0095% | $1.37 | 5 | 24 | <0.0001% |
| Milligan John C.K. IV | Secretary/CEO of subsidiary | 1752703 15.1981% | $1.37 | 3 | 24 | <0.0001% |
| Thompson Tommy G | director | 715600 6.2051% | $1.37 | 13 | 0 | <0.0001% |
| C.S. Finance LLC | 357606 3.1009% | $1.37 | 1 | 0 |
Institutional Investor Ownership
| Helm Capital Management LLC | $2.73M | 10.34 | 1.19M | 0% | +$0 | 0.08 | |
| Clearline Capital LP | $1.23M | 4.64 | 535,340 | +14.83% | +$158,305.46 | 0.12 | |
| Tejara Capital Ltd | $920,436.00 | 3.49 | 401,937 | 0% | +$0 | 0.31 | |
| The Vanguard Group | $887,563.00 | 3.36 | 387,582 | 0% | +$0 | <0.0001 | |
| BlackRock | $310,934.00 | 1.18 | 135,779 | -0.35% | -$1,108.36 | <0.0001 |